Singapore markets close in 1 hour 47 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.3950-0.0750 (-5.10%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4700
Open1.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.3800 - 1.5000
52-week range1.3500 - 7.4000
Volume2,597,308
Avg. volume2,598,796
Market cap854.961M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.2700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
    Business Wire

    CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

    VANCOUVER, Washington, August 03, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organi

  • Business Wire

    CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid

    VANCOUVER, Washington, August 02, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group") were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the "Board").

  • Business Wire

    Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction

    NEW YORK, July 01, 2021--A group of long-time stockholders (the "Nominating Stockholders") of CytoDyn Inc. ("CYDY or the "Company) (OTC: CYDY) today announced that it has sent a notice to CYDY nominating five highly experienced director candidates – Thomas Errico, MD, Bruce Patterson, MD, Paul Rosenbaum, Peter Staats, MD and Melissa Yaeger – to serve on the Company’s Board of Directors.